| Literature DB >> 17629361 |
Daniel A Scott1, Steven F Komjathy, Branda T Hu, Sherryl Baker, Lois A Supan, Carol A Monahan, William Gruber, George R Siber, Stephen P Lockhart.
Abstract
In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17629361 DOI： 10.1016/j.vaccine.2007.06.004
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641